MSFrontier

Supported by one trial

One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.

Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in early MS (CIS or RIS)

early MS (CIS or RIS) · Immune reconstitution (cladribine, alemtuzumab, aHSCT)

One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.

Trials
1
Running now
0
Controlled phase 2/3 trials
1
People in controlled trials
617

Deciding trials (phase 3): 1 met, 0 did not.

Other linked trials: 0

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • ORACLE MSdecides the statusMet main goal

    Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00725985

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-11-02Status changed from Confirmed to Supported by one trial
  • 2026-10-27First listed as Confirmed

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error